| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation W Béguelin, R Popovic, M Teater, Y Jiang, KL Bunting, M Rosen, H Shen, ... Cancer cell 23 (5), 677-692, 2013 | 907 | 2013 |
| The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development A Ortega-Molina, IW Boss, A Canela, H Pan, Y Jiang, C Zhao, M Jiang, ... Nature medicine 21 (10), 1199-1208, 2015 | 425 | 2015 |
| Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trněný, JP Sharman, ... New England Journal of Medicine 386 (4), 351-363, 2022 | 402 | 2022 |
| Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up … AP Kater, JF Seymour, P Hillmen, B Eichhorst, AW Langerak, C Owen, ... Journal of Clinical Oncology 34 (4), 269-277, 2019 | 332 | 2019 |
| CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas Y Jiang, A Ortega-Molina, H Geng, HY Ying, K Hatzi, S Parsa, D McNally, ... Cancer discovery 7 (1), 38-53, 2017 | 258 | 2017 |
| The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation L Wang, A Gural, XJ Sun, X Zhao, F Perna, G Huang, MA Hatlen, L Vu, ... Science 333 (6043), 765-769, 2011 | 250 | 2011 |
| Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation R Popovic, E Martinez-Garcia, EG Giannopoulou, Q Zhang, Q Zhang, ... PLoS genetics 10 (9), e1004566, 2014 | 219 | 2014 |
| Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein BP Nathan, Y Jiang, GK Wong, F Shen, GJ Brewer, RG Struble Brain research 928 (1-2), 96-105, 2002 | 202 | 2002 |
| A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters K Hatzi, Y Jiang, C Huang, F Garrett-Bakelman, MD Gearhart, ... Cell reports 4 (3), 578-588, 2013 | 192 | 2013 |
| Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study AP Kater, JQ Wu, T Kipps, B Eichhorst, P Hillmen, J D’rozario, S Assouline, ... Journal of Clinical Oncology 38 (34), 4042, 2020 | 191 | 2020 |
| A stable transcription factor complex nucleated by oligomeric AML1–ETO controls leukaemogenesis XJ Sun, Z Wang, L Wang, Y Jiang, N Kost, TD Soong, WY Chen, Z Tang, ... Nature 500 (7460), 93-97, 2013 | 171 | 2013 |
| Multi-tiered reorganization of the genome during B cell affinity maturation anchored by a germinal center-specific locus control region KL Bunting, TD Soong, R Singh, Y Jiang, W Béguelin, DW Poloway, ... Immunity 45 (3), 497-512, 2016 | 136 | 2016 |
| Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity S De, R Shaknovich, M Riester, O Elemento, H Geng, M Kormaksson, ... PLoS genetics 9 (1), e1003137, 2013 | 133 | 2013 |
| Epigenomic evolution in diffuse large B-cell lymphomas H Pan, Y Jiang, M Boi, F Tabbò, D Redmond, K Nie, M Ladetto, ... Nature communications 6, 2015 | 127 | 2015 |
| Deep-sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas Y Jiang, D Redmond, K Nie, KW Eng, T Clozel, P Martin, LHC Tan, ... Genome biology 15 (8), 432, 2014 | 117 | 2014 |
| Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax E Tausch, C Schneider, S Robrecht, C Zhang, A Dolnik, J Bloehdorn, ... Blood, The Journal of the American Society of Hematology 135 (26), 2402-2412, 2020 | 116 | 2020 |
| The role of late/slow replication of the FRA16D in common fragile site induction A Palakodeti, Y Han, Y Jiang, MM Le Beau Genes, Chromosomes and Cancer 39 (1), 71-76, 2004 | 112 | 2004 |
| A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma F Morschhauser, P Feugier, IW Flinn, R Gasiorowski, R Greil, Á Illés, ... Blood, The Journal of the American Society of Hematology 137 (5), 600-609, 2021 | 109 | 2021 |
| Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study O Al-Sawaf, C Zhang, T Lu, MZ Liao, A Panchal, S Robrecht, T Ching, ... Journal of Clinical Oncology 39 (36), 4049, 2021 | 107 | 2021 |
| High‐throughput mapping of origins of replication in human cells I Lucas, A Palakodeti, Y Jiang, DJ Young, N Jiang, AA Fernald, ... EMBO reports 8 (8), 770-777, 2007 | 99 | 2007 |
